Berbamine-mediated excess ROS negatively regulates the NF-κB pathway by means of activation of NF-κB inhibitor (IκB) and oxidation of cysteine in the binding region of NF-κB to DNA, thereby inhibiting the development of bladder cancer (Han et al., 2021). The gene discussed is NFKB1; the disease is urinary bladder carcinoma.